Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342730 · ClinicalTrials.gov registry record · NA
Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
A NA study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 127
- Enrollment target
NCT02342730: Completed NA study, sponsored by Case Comprehensive Cancer Center.
NCT02342730 is a NA study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 127 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02342730, a NA study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 127 participants
- Enrollment target
Study Summary
This pilot clinical trial studies whether obese stage I-II endometrial cancer survivors or patients with atypical hyperplasia (abnormal cells in the lining of the uterus) would go see a weight loss specialist if it was recommended by their cancer doctor. Excess body weight or obesity is one of the most common contributors to (causes of) endometrial cancer. Over two-thirds of women who have survived endometrial cancer are obese. Complications of obesity, such as heart disease are often more dangerous than the cancer itself. A weight loss of even 5-10% of excess body weight is associated with improved health. Often, meeting with a doctor or person who is an expert in weight loss (bariatric specialist) is the best way to lose weight and keep it off. Endometrial cancer survivors or patients with atypical hyperplasia who go see a weight loss specialist recommended by their doctor may be able to achieve a healthier body weight.
Primary Outcome
Descriptive statistics will be used. Will be compared using chi square or fisher exact tests.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Medical Chart Review
- BEHAVIORAL Weight Loss Specialist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2014-12-17 |
| Est. Completion | 2015-05-18 |
| Phase | NA |
What the finished NCT02342730 record still lists
NCT02342730 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02342730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02342730 about?
NCT02342730 is a clinical study titled "Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia". This pilot clinical trial studies whether obese stage I-II endometrial cancer survivors or patients with atypical hyperplasia (abnormal cells in the lining of the uterus) would go see a weight loss specialist if it was recommended by their cancer doctor. Excess body weight or obesity is one of the m...
What is the current status of trial NCT02342730?
This trial is currently completed. It is a NA study. The enrollment target is 127 participants. The study started on 2014-12-17. Estimated completion is 2015-05-18.
What interventions are being tested in trial NCT02342730?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Medical Chart Review (OTHER), Weight Loss Specialist (BEHAVIORAL).
Who is sponsoring clinical trial NCT02342730?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02342730's enrollment target sits among peer trials
127 749th of 2000 higher than 1,252 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI